Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766815 | 0.85 | THRB (0.34) | APEX1THRBTDP1 | |
| SCHEMBL5863723 | 0.79 | THRB (0.46) | APEX1THRBTDP1PDK2 | |
| SCHEMBL6766347 | 0.79 | APEX1 (0.35) | APEX1THRBTDP1PDK2 | |
| SCHEMBL7052018 | 0.78 | SIGMAR1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL6777668 | 0.78 | THRB (0.44) | APEX1THRBTDP1PDK2 | |
| SCHEMBL6777664 | 0.77 | PDK2 (0.40) | APEX1THRBTDP1PDK2 | |
| Propionamide SCHEMBL27574379 | 0.73 | THRB (0.38) | APEX1THRBTDP1 | |
| SCHEMBL6766699 | 0.73 | PDK2 (0.40) | APEX1THRBTDP1PDK2 | |
| SCHEMBL6769789 | 0.72 | AKR1C1 (0.35) | APEX1THRBTDP1 | |
| SCHEMBL17742236 | 0.72 | THRB (0.53) | APEX1THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | APEX1 4003/4885THRB 1353/4885TDP1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.